Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 511-517

  Bousserouel, Souad ^a,b   Gosse, Francine ^a,b   Bouhadjar, Mourad ^b   Soler, Luc ^b   Marescaux, Jacques ^b   Raul, Francis ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b IRCAD   (France)

Author keywords

Aberrant crypt foci; Chemoprevention; Colorectal cancer; Gene expression; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA DEFENSIN; AZOXYMETHANE; INTERLEUKIN 1BETA; MATRILYSIN; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN BAX; PROTEIN BCL 2; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; INNATE IMMUNITY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; AZOXYMETHANE; CARCINOGENS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MALE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, WISTAR; TIME FACTORS;

EID: 76649101811     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000663     Document Type: Article

References (50)

1. Lieberman DA: Screening for colorectal cancer. Clin Cornerstone 4: 1-10, 2002.
2. Benamouzig R and Chaussade S: La chimioprevéntion du cancer colorectal. Presse Med 31: 124-128, 2002.
3. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2; expression and colorectal cancer. JAMA 282: 1254-1257, 1999.
4. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529-1536, 1998.
5. Thun M: Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology 11: 371-374, 2000.
6. Baron JA: Aspirin and NSAIDS for the prevention of colorectal cancer. Recent Results Cancer Res 181: 223-229, 2009.
7. Ulrich CM, Bigler J and Potter JD: Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140, 2006.
8. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M and Moher D: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 365-375, 2007.
9. Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993.
10. Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R and Lyubimov A: Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Chem Biol Interact 179: 233-239, 2009.
11. Wargovich MJ, Chen CD, Harris C, Yang E and Velasco M: Inhibition of aberrant crypt growth by non-steroidal antiinflammatory agents and differentiation agents in the rat colon. Int J Cancer 60: 515-519, 1995.
12. Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049-1054, 1994.
13. Craven PA and DeRubertis FR: Effects of aspirin on 1,2-dimethylhydrazine- induced colonic carcinogenesis. Carcinogenesis 13: 541-546, 1992.
14. Craven PA, Thornburg K and DeRubertis FR: Sustained increase in the proliferation of rat colonic mucosa during chronic treatment with aspirin. Gastroenterology 94: 567-575, 1988.
15. Craven PA, Saito R and DeRubertis FR: Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 72: 1365-1375, 1983.
16. DeRubertis FR, Craven PA and Saito R: 16,16-Dimethyl prostaglandin E2 suppresses the increases in the proliferative activity of rat colonic epithelium induced by indomethacin and aspirin. Gastroenterology 89: 1054-1063, 1985.
17. Kuwayama H and Eastwood GL: Effects of water immersion restraint stress and chronic indomethacin ingestion on gastric antral and fundic epithelial proliferation. Gastroenterology 88: 362-365, 1985.
18. Eastwood GL and Quimby GF: Effect of chronic aspirin ingestion on epithelial proliferation in rat fundus, antrum, and duodenum. Gastroenterology 82: 852-856, 1982.
19. Deschner EE, Long FC, Hakissian M and Herrmann SL: Differential susceptibility of AKR, C57BL/6J, and CF1 mice to 1,2-dimethylhydrazine-induced colonic tumor formation predicted by proliferative characteristics of colonic epithelial cells. J Natl Cancer Inst 70: 279-282, 1983.
20. Deschner EE, Winawer SJ, Katz S, Katzka I and Kahn E: Proliferative defects in ulcerative colitis patients. Cancer Invest 1: 41-47, 1983.
21. Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon cancer chemoprevention in rats, mice and humans. Eur J Cancer 41: 1911-1922, 2005.
22. Reddy BS: Studies with azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 44: 26-35, 2004.
23. Rudolph RE, Domonitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP and Potter JD: Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 14: 605-608, 2005.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
25. Gunter MJ: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15: 1126-1131, 2006.
26. Lu Q, Jiang B, Lin C and Shan T: Dark qberrant crypt foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat. J Exp Clin Cancer Res 27: 26, 2008.
27. Ramasundara M, Leach ST, Lemberg DA and Day AS: Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24: 202-208, 2009.
28. Reddy BS and Rao CV: Chemoprophylaxis of colon cancer. Curr Gastroenterol Rep 7: 389-395, 2005.
29. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
30. Macejova D and Brtko J: Chemically induced carcinogenesis: a comparison of 1-methyl-1-nitrosurea, 7,12-dimethyl-benzanthracene, diethyl-nitroso-amine and azoxymethane models. Endocr Regul 35: 53-59, 2001.
31. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339: 1277-1284, 1998.
32. Molatore S and Ranzani GN: Genetics of colorectal polyps. Tech Coloproctol 8 (Suppl 2): s240-s242, 2004.
33. Gout S and Huot J: Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 1: 69-83, 2008.
34. Ouyang LH and Huang C: Inflammation, a key event in cancer development. Mol Cancer Res 4: 221-233, 2006.
35. Perwez Hussain S and Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121: 2373-2380, 2007.
36. Raul F, Gossé F, Osswald AB, Bouhadjar M, Foltzer-Jourdainne C, Marescaux J and Soler L: Follow-up of tumor development in the colons of living rats and implications for chemoprevention trials: assessment of aspirin-difluoromethylornithine combination. Int J Oncol 31: 89-95, 2007.
37. Gupta RA and Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21, 2001.
38. Marnett LJ and DuBois RN: COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42: 55-80, 2002.
39. Zucker S and Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23: 101-107, 2004.
40. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN and Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10: 1033-1043, 2002.
41. Papo N and Shai Y: Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62: 784-790, 2005.
42. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y and Kim JS: Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 118: 2490-2497, 2006.
43. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV and Radford-Smith GL: Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 57: 903-910, 2008.
44. Friedl A, Stoesz SP, Buckley P and Gould MN: Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 31: 433-441, 1999.
45. Shi J, Aono S, Lu W, Ouellette AJ, Hu X, Ji Y, Wang L, Lenz S, van Ginkel FW, Liles M, Dykstra C, Morrison EE and Elson CO: A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol 179: 1245-1253, 2007.
46. Devireddy LR, Teodoro JG, Richard FA and Green MR: Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 293: 829-834, 2001.
47. Aarbiou J, Tjabringa GS, Verhoosel RM, Ninaber DK, White SR, Peltenburg LT, Rabe KF and Hiemstra PS: Mechanisms of cell death induced by the neutrophil antimicrobial peptides alphadefensins and LL-37. Inflamm Res 55: 119-127, 2006.
48. Lai MY, Huang JA, Liang ZH, Jiang HX and Tang GD: Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol 14: 4227-4233, 2008.
49. Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene 22: 9030-9040, 2003.
50. Buckley AR: Lessons from anticancer research might provide new insights into mechanisms of hormone action. Trends Endocrinol Metab 12: 87-89, 2001.